<i>CYP2C19</i> Genotype-Guided Antiplatelet Therapy After Percutaneous Coronary Intervention in Diverse Clinical Settings.

While the reduction in major atherothrombotic events between groups at 12 months did not reach statistical significance (HR, 0.66; 95% CI 0.43–1.02, P =0.06), post hoc analysis showed a significant reduction in events at 90 days (HR, 0.21; 95% CI 0.08–0.54, P =0.001). 9 We similarly observed lower atherothrombotic event rates in LOF allele carriers treated with alternative therapy versus clopidogrel at 90 days (adjusted HR, 0.40; 95% CI 0.23–0.71, P =0.002), and unlike TAILOR‐PCI, the difference was also evident at 12 months (adjusted HR, 0.56; 95% CI 0.39–0.82, P =0.003).

also in 111,027 other papers